Abzena PLC Notice of AGM (4544M)

TIDMABZA

RNS Number : 4544M

Abzena PLC

28 July 2017

Abzena plc

Notice of AGM

Cambridge, UK, 28 July 2017 - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that its Annual General Meeting (AGM) will be held at 10:00am on Thursday, 14 September 2017 at Babraham Research Campus, Babraham, Cambridge CB22 3AT.

A copy of the Notice of AGM, Form of Proxy, and 2017 Annual Report are available at http://www.abzena.com/about/investor-information/documents/

-Ends-

Enquiries:

 
   Abzena plc 
    John Burt, Chief Executive 
    Officer Julian Smith, Chief 
    Financial Officer                  [phone] 
   Numis (Nominated Adviser and 
    Broker) 
    Clare Terlouw / James Black        [phone] 
    / Paul Gillam                       1000 
 
   N+1 Singer (Joint Broker)           [phone] 
    Aubrey Powell / Liz Yong            3000 
   Instinctif Partners                 [phone] 
    Melanie Toyne Sewell / Alex         2020 
    Shaw                                [e-mail] 
 

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

-- Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

   --   Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; 
   --   Cell line development for the manufacture of recombinant proteins and antibodies; 

-- Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

-- Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

   --   Proprietary site-specific conjugation technologies and novel payloads for ADC development; and 
   --   GMP manufacturer of ADC linkers, payloads & combined linker-payloads. 

For more information, please see www.abzena.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOASEAFFAFWSESW

(END) Dow Jones Newswires

July 28, 2017 07:27 ET (11:27 GMT)